# A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

> **NCT02115035** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Arkansas**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Vermurafenib

## Key facts

- **NCT ID:** NCT02115035
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-07
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding issues
- **Last updated:** 2014-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02115035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02115035, "A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02115035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*